Inflammation/Immunology

Osutidine is a selective histamine H₂ receptor antagonist, can effectively inhibit histamine-stimulated gastric acid secretion. Osutidine does not affect [¹⁴C]aminopyrine accumulation stimulated by carbachol or dibutyryl-cAMP. Osutidine is insurmountable and includes non-competitive inhibition. Osutidine can be used for the study of gastric mucosal injury.

all-cis-4,7,10,13,16-Docosapentaenoic acid methyl ester (all-cis-4,7,10,13,16-DPA methyl ester) is the methyl ester derivative of all-cis-4,7,10,13,16-Docosapentaenoic acid, that can be used as a nutritional supplement to increase all-cis-4,7,10,13,16-Docosapentaenoic acid intake. all-cis-4,7,10,13,16-Docosapentaenoic acid is a long-chain polyunsaturated fatty acid, that plays a role in cardiovascular health, neuroprotection, and inflammation regulation.

(Rac)-Telmesteine (Standard) is the analytical standard of (Rac)-Telmesteine (HY-108285). This product is intended for research and analytical applications. (Rac)-Telmesteine is a protease inhibitor and is thus a suitable enzyme stabilizer extracted from patent WO 2017220302 A1, compound II-1. (Rac)-Telmesteine can be used as an enzyme stabilizer in protease-containing detergents and cleaning agents.

Sudachitin is an orally active compound that potently inhibits mouse PDE1C and human PDE4B, with IC₅₀ values of 5.0 μM and 15.0 μM, respectively. Sudachitin upregulates Sirt1 and PGC‑1α expression in skeletal muscle to regulate energy metabolism and promote mitochondrial biogenesis. Sudachitin improves lipid metabolism, glucose tolerance, insulin sensitivity, energy expenditure, and fatty acid β‑oxidation. Sudachitin activates p38MAPK signaling, induces HSP27 phosphorylation and caspase‑dependent apoptosis, and blocks EGF‑driven keratinocyte migration and proliferation. Sudachitin suppresses LPS‑induced TNF‑α, NO, and iNOS expression in macrophages and shows potent anti‑inflammatory activity. Sudachitin can be used for the research of metabolic syndrome, type 2 diabetes, and psoriasis..

Human CCR1 mRNA encodes the human C-C motif chemokine receptor 1 (CCR1) protein, a member of the beta chemokine receptor family. Chemokines and their receptors are critical for the recruitment of effector immune cells to the site of inflammation.

PHD-IN-5 (ISM4808) is an orally active PHD inhibitor that can be used for studying anemia in chronic kidney disease.

γ-Isofagarine (Iso-γ-fagarine) is an alkaloid that can be isolated from the root bark of Dictamnus angustifolius. Dictamnus angustifolius has been used in the research of rheumatism, bleeding, itching, jaundice, chronic hepatitis, skin diseases, etc.

Human PECAM1 mRNA encodes the human platelet and endothelial cell adhesion molecule 1 (PECAM1) protein, a member of the immunoglobulin superfamily. PECAM1 is likely involved in leukocyte migration, angiogenesis, and integrin activation.

Ki20227 (Standard) is the analytical standard of Ki20227 (HY-10408). This product is intended for research and analytical applications. Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC₅₀s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction.

Trifarotene (Standard) is the analytical standard of Trifarotene. This product is intended for research and analytical applications. Trifarotene (CD5789) is a potent and selective RARγ agonist. Trifarotene (CD5789) shows ∼65-fold and ∼16-fold selectivitiy for the RARγ (EC₅₀=7.7 nM) over RARα (EC₅₀=500 nM) and RARβ (EC₅₀=125 nM), respectively.

ALXR-agonist-6 (compound 36) is an ALXR agonist with the EC₅₀ values of >10 μM for Ca²⁺ flux in CHO recombinant cells co-expressing hFPRL1.

Tyk2-IN-26 (compound 18) is a TYK2 inhibitor that suppresses TYK2/STAT signaling induced by IL-23 and IFNα, with IC₅₀ values all below 30 nM. Tyk2-IN-26 is applicable to research related to TYK2, IL-23, type I IFN signaling, as well as inflammatory immunity.

1,1-Diphenyl-4-(pyrrolidin-1-yl)but-2-yn-1-ol is an anticholinergic agent. 1,1-Diphenyl-4-(pyrrolidin-1-yl)but-2-yn-1-ol has the potential for the research of bronchial asthma. 1,1-Diphenyl-4-(pyrrolidin-1-yl)but-2-yn-1-ol is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

A-79175 is a potent 5-lipoxygenase inhibitor that inhibits leukotriene formation. A-79175 is promising for research of various allergic and inflammatory diseases including asthma, allergic rhinitis, rheumatoid arthritis and inflammatory bowel disease.

IMG-2005 is a TLR signaling pathway inhibitor. IMG-2005 mimics the Toll/interleukin-1 receptor (TIR) domain of MyD88, thereby preventing its homodimerization, which causes damage to tracheal epithelial cells and triggers pulmonary immune diseases.

(R)-MrgprX2 antagonist-3 (compound E118) is an MrgprX2 antagonist extracted from patent WO2021092240A1, example E118. (R)-MrgprX2 antagonist-3 can be used for the research of inflammatory disorders of the skin.

C14-Ala-D-Glu-(γ-meso)-LAN-Gly (OH) (C14-A-iE-LAN-G) is a NOD1 agonist and immunomodulator. C14-Ala-D-Glu-(γ-meso)-LAN-Gly (OH) promotes IL-10 production in cells. C14-Ala-D-Glu-(γ-meso)-LAN-Gly (OH) is applicable to research related to experimental autoimmune encephalomyelitis and colitis.

MMP145 (compound 27) is a potent, selective and orally active MMP-12 inhibitor. MMP145 is effective in inflammation and asthma reasearch.

CAY10657 is an inhibitor for NF-κB pathway. CAY10657 downregulates expressions of proinflammatory cytokine (IL-6) and chemokine (MCP-1), and thus exhibits anti-inflammatory efficacy against meningitis induced by Streptococcus suis.

Lifitegrast-d₆ (SAR 1118-d₆) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease.